ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
AnaptysBio Inc

AnaptysBio Inc (ANAB)

19.83
-1.64
(-7.64%)
Closed April 18 4:00PM
19.83
0.00
( 0.00% )
Pre Market: 4:09AM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
19.83
Bid
15.00
Ask
31.72
Volume
-
0.00 Day's Range 0.00
13.36 52 Week Range 27.50
Market Cap
Previous Close
19.83
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
327,005
Shares Outstanding
26,763,081
Dividend Yield
-
PE Ratio
-3.24
Earnings Per Share (EPS)
-6.11
Revenue
17.16M
Net Profit
-163.62M

About AnaptysBio Inc

AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery techno... AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
AnaptysBio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ANAB. The last closing price for AnaptysBio was $19.83. Over the last year, AnaptysBio shares have traded in a share price range of $ 13.36 to $ 27.50.

AnaptysBio currently has 26,763,081 shares outstanding. The market capitalization of AnaptysBio is $530.71 million. AnaptysBio has a price to earnings ratio (PE ratio) of -3.24.

ANAB Latest News

Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced...

Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference

SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-5.06-20.329449578124.8924.9419.78530414721.30500634CS
4-4.58-18.762802130324.4125.6219.78539512521.64502754CS
12-4.02-16.855345911923.8527.519.78532700523.22610633CS
261.417.6547231270418.4227.513.3628748221.10795165CS
52-2.33-10.514440433222.1627.513.3625918420.31902187CS
156-1.74-8.0667593880421.5737.8913.3624536223.68110649CS
260-53.95-73.122797506173.7879.099.1632755823.69108765CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RWODRedwoods Acquisition Corporation
$ 17.74
(121.84%)
130.08k
ZCMDZhongchao Inc
$ 2.62
(80.69%)
1.48M
WLGSWang and Lee Group Inc
$ 0.758
(51.60%)
154.75k
HUBCHub Cyber Security Ltd
$ 1.64
(27.13%)
1.79M
RELIReliance Global Group Inc
$ 0.339
(23.23%)
3.31k
MBOTMicrobot Medical Inc
$ 0.36
(-59.55%)
4
BGLCBioNexus Gene Lab Corporation
$ 0.6121
(-27.87%)
26.97k
ISPCiSpecimen Inc
$ 0.34
(-19.24%)
70.25k
TIRXTian Ruixiang Holdings Ltd
$ 0.6521
(-18.49%)
76.13k
AGBAAGBA Group Holding Ltd
$ 0.88
(-14.56%)
223.04k
HUBCHub Cyber Security Ltd
$ 1.64
(27.13%)
1.79M
ZCMDZhongchao Inc
$ 2.62
(80.69%)
1.48M
SQQQProShares UltraPro Short QQQ
$ 12.40
(2.73%)
1.35M
SPCBSuperCom Ltd
$ 0.294
(22.50%)
1.05M
SINTSiNtx Technologies Inc
$ 0.0375
(-6.25%)
815.61k

ANAB Discussion

View Posts
gfp927z gfp927z 2 years ago
HighPeaks, The NY Times article was high profile, but the connection to ANAB isn't readily apparent.

Even with the partial sale/monetization of the revenue stream from dostarlimab in December, the drug is also being studied by Glaxo for other cancer types (endometrial, non-small cell lung, ovarian, and mismatch repair deficient solid tumors). One question to answer is whether the monetization deal with Sagard was only for colorectal, or for all the indications? Probably for all, but I'll have to do more research.

ANAB has numerous other programs and a large pile of cash, so looks interesting. But investing in biotech requires a ton of research, but even then you still don't know what you have, and landmines are everywhere. Better to invest in 'what you know', as Buffett recommends :o)




---
👍️0
HighPeaks HighPeaks 2 years ago
Thanks TP. Yeah this has the potential to really be a big mover. So surprised no one has made the connection between this potential miracle drug and $ANAB receiving royalties on it(as it’s originator). GSK is the collaborator who has just commercialized it but it’s ANAB invention.
👍️0
tedpeele tedpeele 2 years ago
Tremendous find HighPeaks. .You have been early on quite a few big movers. I'm thinking this is yet another one.

Will be watching this closely...thanks.
👍️0
HighPeaks HighPeaks 2 years ago
According to this link ANAB gets 8-25% royalties from Dostarlimab. This drug has recently shown phenomenal results in a trial at Memorial Sloan Kettering Hospital. All patients fully recovered from rectal cancer.
https://www.globenewswire.com/fr/news-release/2020/10/26/2114250/0/en/AnaptysBio-and-GlaxoSmithKline-Amend-Strategic-Immuno-Oncology-Collaboration.html
👍️0
TFMG TFMG 4 years ago

$ANAB | #Anaptysbio Spikes After Drug Designation


Nice spike in the afterhours session, lets hope we
can get some continuation tomorrow.
Target $29.00 to Fib Golden Pocket
Also a very large gap to fill at $35.00
AnaptysBio gets orphan drug designation of imsidolimab for pustular psoriasis
PLEASE GIVE US A LIKE IF YOU FIND OUR CONTENT HELPFUL, THANK YOU.


👍️0
LoveItInBishop LoveItInBishop 4 years ago
RSI @ 16. laughable. Zacks has positive take. https://finance.yahoo.com/news/anaptysbio-enters-oversold-territory-135501475.html
👍️0
ClayTrader ClayTrader 4 years ago
* * $ANAB Video Chart 11-13-19 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 4 years ago
* * $ANAB Video Chart 11-08-19 * *

Link to Video - click here to watch the technical chart video

👍️0
waterchaser waterchaser 4 years ago
LOL! Twitter PnD. Buyer beware.
👍️0
420man 420man 4 years ago
Once the real bounce starts it will be fast....
👍️0
Crazy Money Crazy Money 4 years ago
$10 to da moon
👍️0
420man 420man 4 years ago
This will bounce..... 15 AH
👍️0
RJ Trotts RJ Trotts 4 years ago
trying to bounce back over $11, hoping for more
👍️0
TaxiCaT TaxiCaT 4 years ago
Ouch -
👍️0
celle celle 5 years ago
Nothing happen here?
👍️0
manny371 manny371 6 years ago
This stock is making noise! Bought in Sept $ANAB
👍️0

Your Recent History

Delayed Upgrade Clock